Insmed director sells 25,000 shares at $124
INSMED director David R. Brennan sold 25,000 INSM shares and now reports 39,238 shares held directly plus 60,000 shares held indirectly through a spouse trust.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
INSMED Inc (INSM) director David R. Brennan reported selling 25,000 shares of common stock on September 9, 2026 in a sale described as an open market or private transaction at $124.00 per share. Following this sale, he directly holds 39,238 shares of INSMED common stock.
The filing also reports indirect ownership of 60,000 shares held through a spouse revocable trust as of the same date. No Rule 10b5-1 trading plan is reported for these transactions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 25,000 | $124.00 | $3.10M |
| Holding | Common Stock | -- | -- | -- |
Key Figures
Key Terms
open market or private transaction market
indirect ownership financial
spouse revocable trust financial
Rule 10b5-1 trading plan regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did INSM director David R. Brennan report?
Was the INSM insider sale made under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.